Americans generally pay more for brand-name prescription drugs than patients in other wealthy countries. The system grants temporary monopolies to fund research, and the dispute is over whether that bargain has drifted too far toward the seller.
Patents and regulatory exclusivity give a manufacturer a period without direct competition, during which it can set prices freely. When exclusivity ends, generic or biosimilar entry usually reduces prices sharply.
Between manufacturer and patient sit insurers, pharmacy benefit managers, wholesalers, and pharmacies. Rebates negotiated along this chain mean list prices and actual net prices can differ substantially, and patient cost-sharing is sometimes calculated on the higher figure.
Drug development is expensive and most candidates fail. How much of the cost of a marketed drug reflects that failure rate, and how much reflects what the market will bear, is contested and difficult to establish from public data.